Literature DB >> 15201378

Spectroscopy and serial diffusion MR findings in hGH-Creutzfeldt-Jakob disease.

C Oppenheim1, M Zuber, D Galanaud, M Detilleux, F Bolgert, J L Mas, J Chiras, J F Meder.   

Abstract

This report describes the magnetic resonance imaging (MRI) findings in two patients fulfilling the diagnostic criteria for human growth hormone Creutzfeldt-Jakob disease, who initially had pronounced bilateral DWI/FLAIR (diffusion weighted imaging/fluid attenuated inversion recovery) hyperintensities in the basal ganglia, with decreased apparent diffusion coefficient (ADC) values (range, 58-82% of normal). MRI spectroscopy, obtained in one case, showed decreased N-acetyl aspartate/creatine (NAA/Cr) ratio in the atrophic vermis (0.79; normal: mean, 1.20; SD, 0.13), despite the lack of DWI/FLAIR signal changes, whereas NAA/Cr was normal in the putamina (1.6; normal: mean, 1.56; SD, 0.17), despite striking DWI signal changes and decreased ADC values (60% of normal). Serial DWI, obtained in the other case, showed a progressive disappearance of DWI hypersignal of the basal ganglia replaced by pronounced atrophy. Data from these two patients suggest that restricted diffusion associated with a normal NAA value might indicate spongiform changes of still viable cells, and that any subsequent regression of the DWI signal changes, atrophy, or decreased NAA values could be related to progressive neuronal death.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15201378      PMCID: PMC1739146          DOI: 10.1136/jnnp.2003.020172

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

Review 1.  Using NMR spectroscopy to investigate the role played by copper in prion diseases.

Authors:  Rawiah A Alsiary; Mawadda Alghrably; Abdelhamid Saoudi; Suliman Al-Ghamdi; Lukasz Jaremko; Mariusz Jaremko; Abdul-Hamid Emwas
Journal:  Neurol Sci       Date:  2020-04-24       Impact factor: 3.307

Review 2.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

3.  Combined diffusion imaging and MR spectroscopy in the diagnosis of human prion diseases.

Authors:  Damien Galanaud; S Haik; M G Linguraru; J-P Ranjeva; B Faucheux; E Kaphan; N Ayache; J Chiras; P Cozzone; D Dormont; J-P Brandel
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-29       Impact factor: 3.825

4.  Diffusion-weighted imaging and magnetic resonance spectroscopy of sporadic Creutzfeldt-Jakob disease: correlation with clinical course.

Authors:  Jae Hyoung Kim; Byung Se Choi; Cheolkyu Jung; YoungHee Chang; SangYun Kim
Journal:  Neuroradiology       Date:  2011-01-11       Impact factor: 2.804

5.  Neuroimaging in human prion disease: Searching in the mist.

Authors:  Panayotis Ioannides; Dimitris Karacostas
Journal:  World J Radiol       Date:  2009-12-31

6.  MRI detection of the cerebellar syndrome in Creutzfeldt-Jakob disease.

Authors:  Oren S Cohen; Chen Hoffmann; Hedok Lee; Joab Chapman; Robert K Fulbright; Isak Prohovnik
Journal:  Cerebellum       Date:  2009-05-01       Impact factor: 3.847

Review 7.  Neuroimaging findings in human prion disease.

Authors:  R G Macfarlane; S J Wroe; J Collinge; T A Yousry; H R Jäger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-29       Impact factor: 10.154

8.  Serial Magnetic Resonance Imaging in Creutzfeldt-Jakob Disease: a Case Report and Literature Review.

Authors:  Ahmed H Qavi; Tasnim F Imran; Zachariah Hasan; Fariha Ilyas; Usman Ghani; Salman Assad; Shabih Hasan
Journal:  Cureus       Date:  2017-03-14

9.  The insomnia phenotype in genetic Creutzfeldt-Jakob disease based on the E200K mutation.

Authors:  Eva Feketeova; Dominika Jarcuskova; Alzbeta Janakova; Marianna Vitkova; Jozef Dragasek; Zuzana Gdovinova
Journal:  Prion       Date:  2019-01       Impact factor: 3.931

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.